SomnoMed Ltd (ASX: SOM) Share Price and News
Price
–
Movement
– ( )
(20 mins delayed)
52 Week Range
– - –
1 Year Return
SomnoMed Ltd Chart and Price Data
Fundamentals Data provided by Morningstar.
Data provided by Morningstar.
Market Cap
$136.15 million
P/E Ratio
136.99
Dividend Yield
0.00%
Shares Outstanding
216.11 million
Earnings per share
-0.049
Dividend per share
N/A
Year To Date Return
36.96%
Earnings Yield
0.73%
Franking
-
Share Price
–
Day Change
– ( )
52 Week Range
– - –
Yesterday's Close
–
Today's Open
–
Days Range
– - –
Volume
–
Avg. Volume (1 month)
–
Turnover
–
SomnoMed Ltd (ASX: SOM)
Latest News
Investing
8 shares you need to watch on Tuesday
Investing
Why the Somnomed Limited share price surged 11% today
Investing
Why these 4 ASX shares have started the week with solid gains
Investing
Why these 4 ASX shares have climbed higher today
Investing
Why these 4 ASX shares have sunk like stones today
Investing
S&P/ASX 200 finishes higher Wednesday: 9 shares you missed
Investing
Why the Somnomed Limited share price is cratering today
Investing
Why Somnomed Limited is among 4 shares falling today
Investing
Why MesoBLAST limited is rocketing higher on FDA approval
Investing
Why these 4 shares are soaring higher today
Investing
ASX 200 slammed: 12 shares you should have been watching
Investing
Is ResMed Inc. (CHESS) the best new software company on the ASX?
SOM ASX Announcements
An announcement is considered as "Price Sensitive" if it is thought that it may have an impact on the price of the security.
| Date | Announcement | Price Sensitive? | Time | No. of Pages | File Size |
|---|
About SomnoMed Ltd
SomnoMed Ltd produces and sells oral treatment of sleep-related disorder devices. It manufactures and designs premium oral appliances for the treatment of sleep-disordered breathing relieving conditions. Its products include SomnoDent, SomTabs, Som Morning Repositioner and others. Its geographical segments include North America, Europe, and Asia-Pacific. Business operations consist of the production and sale of products treating sleep-disordered breathing, which is the onlyreportable segment. Substantial revenue is realized from the European region.
SOM Share Price History Data provided by Morningstar.
| Date | Close | Change | % Change | Volume | Open | High | Low |
|---|---|---|---|---|---|---|---|
| 20 Jun 2025 | $0.63 | $-0.01 | -1.57% | 60,329 | $0.61 | $0.64 | $0.58 |
| 19 Jun 2025 | $0.64 | $-0.02 | -3.05% | 70,170 | $0.63 | $0.64 | $0.60 |
| 18 Jun 2025 | $0.66 | $0.04 | 6.45% | 23,764 | $0.63 | $0.66 | $0.63 |
| 17 Jun 2025 | $0.62 | $-0.01 | -1.60% | 144,197 | $0.62 | $0.63 | $0.59 |
| 16 Jun 2025 | $0.63 | $-0.01 | -1.57% | 4,668 | $0.65 | $0.65 | $0.59 |
| 13 Jun 2025 | $0.64 | $0.01 | 1.59% | 145,403 | $0.63 | $0.67 | $0.62 |
| 12 Jun 2025 | $0.63 | $0.04 | 6.72% | 36,902 | $0.60 | $0.64 | $0.60 |
| 11 Jun 2025 | $0.60 | $0.01 | 1.69% | 1,595 | $0.59 | $0.61 | $0.59 |
| 10 Jun 2025 | $0.59 | $-0.04 | -6.35% | 13,595 | $0.63 | $0.63 | $0.59 |
| 06 Jun 2025 | $0.63 | $0.01 | 1.61% | 43,740 | $0.62 | $0.63 | $0.56 |
| 05 Jun 2025 | $0.62 | $-0.02 | -3.15% | 7,233 | $0.64 | $0.64 | $0.62 |
| 04 Jun 2025 | $0.64 | $0.05 | 8.47% | 29,650 | $0.59 | $0.64 | $0.59 |
| 03 Jun 2025 | $0.59 | $-0.01 | -1.67% | 40,518 | $0.59 | $0.60 | $0.59 |
| 02 Jun 2025 | $0.60 | $0.03 | 5.24% | 116,817 | $0.55 | $0.60 | $0.55 |
| 29 May 2025 | $0.57 | $-0.02 | -3.36% | 1,381 | $0.56 | $0.57 | $0.56 |
| 28 May 2025 | $0.60 | $0.01 | 1.71% | 59,938 | $0.56 | $0.60 | $0.53 |
| 27 May 2025 | $0.59 | $0.02 | 3.54% | 144,023 | $0.56 | $0.60 | $0.55 |
| 26 May 2025 | $0.57 | $-0.01 | -1.74% | 1,881 | $0.57 | $0.59 | $0.57 |
| 23 May 2025 | $0.58 | $0.02 | 3.64% | 9,789 | $0.55 | $0.58 | $0.52 |
| 22 May 2025 | $0.55 | $-0.05 | -8.33% | 63,667 | $0.58 | $0.58 | $0.55 |
Director Transactions Data provided by Morningstar.
| Date | Director | Type | Amount | Value | Notes |
|---|---|---|---|---|---|
| 05 Dec 2024 | Michael Gordon | Issued | 500,000 | $227,500 |
Issue of options.
|
| 05 Dec 2024 | Benjamin(Ben) Gisz | Issued | 300,000 | $136,500 |
Issue of options.
|
| 05 Dec 2024 | Gaetano (Guy) Russo | Buy | 665,000 | $294,661 |
On-market trade.
|
| 05 Dec 2024 | Gaetano (Guy) Russo | Issued | 700,000 | $318,500 |
Issue of options.
|
| 23 Sep 2024 | Karen Borg | Buy | 12,238 | $5,384 |
On-market trade. share approximately
|
| 09 Sep 2024 | Karen Borg | Buy | 25,593 | $10,749 |
On-market trade. share approximately
|
| 01 Jul 2024 | Karen Borg | Issued | 575,000 | $155,250 |
Issue of options.
|
| 01 Jul 2024 | Amrita Blickstead | Issued | 575,000 | $155,250 |
Issue of options.
|
| 28 Jun 2024 | Amrita Blickstead | Issued | 750,000 | $189,375 |
Issue of options.
|
| 28 Jun 2024 | Karen Borg | Issued | 750,000 | $189,375 |
Issue of options.
|
Directors & Management Data provided by Morningstar.
| Name | Title | Start Date | Profile |
|---|---|---|---|
| Mr Michael Gordon | Non-Executive Director | Aug 2020 |
Mr Gordon is a Director of K Sleep Holdings Pty Limited (Koala), a direct-to-consumer household goods retailer. Michael was previously the CFO of Rokt, a marketing technology company and CFO of Different Technologies, a property technology company. He started his career with PricewaterhouseCoopers spending 10 years with them in South Africa, the United Kingdom and Australia specialising in the retail and pharmaceutical industries with experience in audit, taxation, and corporate finance. He is also Chair of Risk Committee.
|
| Mr Gaetano (Guy) Alfred Gerrard Russo | Non-Executive ChairmanNon-Executive Director | Aug 2020 |
Mr Russo has commercial and customer-focussed background working in Australia and internationally. Previously, Guy has served as CEO, Wesfarmers Department Store Division (Kmart & Target); Managing Director, Kmart Australia & NZ; President, McDonald's Greater China; CEO McDonald's Australia Ltd and Chairman of Ronald McDonald House Children's Charities. He is member of the Risk Committee.
|
| Mr Andrew Price | Non-Executive Director | Jan 2025 |
Mr Price is an executive in the medical device industry, has spent the last 25 years at ResMed in various senior roles. Prior to finishing his employment with ResMed, Andrew was Chief Supply Chain Officer. Andrew held roles at ResMed across product development, project management and business development globally.
|
| Mr Benjamin(Ben) Gisz | Non-Executive Director | Oct 2024 |
--
|
| Ms Amrita Blickstead | Executive DirectorJoint CEO | Feb 2024 |
Ms Blickstead has strategic, sales and marketing, and product development expertise. She has experience in retail, ecommerce, medical devices and has been an advocate for diversity & inclusion. Amrita is the former Chief Operating and Marketing Officer at eBay Australia & New Zealand and over her 10-year tenure led many different areas of the business across Strategy, Operations, Marketing, Sales, Loyalty, Advertising, Pricing, Consumer Selling, Cross Border Trade, Shipping and Small & Medium Business. Prior to eBay, Amrita established her career as a Management Consultant at Port Jackson Partners, and a Biomedical Engineer at Ventracor and Cochlear.
|
| Ms Karen Borg | Executive DirectorJoint CEO | Feb 2024 |
Ms Borg has held senior roles in FTSE 100-250 medical device, technology, consumer products and government services organisations. Karen was most recently the Chief Executive Officer for Catholic Healthcare Ltd and prior to this was the CEO of Healthdirect and the inaugural CEO of Jobs for NSW. Karen began her career in the fast-moving consumer goods sector and worked for Goodman Fielder, Nestle and Revlon in global business development and marketing.
|
| Mr Terence Anthony Flitcroft | Company Secretary |
-
|
|
| Darren Collins | CFO |
-
|
|
| Terence Anthony Flitcroft | Company Secretary |
-
|
|
| Mark Harding | Vice President - Global Marketing |
-
|
|
| Van Kleef | Vice President - Marketing and Sales Europe |
-
|
Top Shareholders Data provided by Morningstar.
| Name | Shares | Capital |
|---|---|---|
| Hsbc Custody Nominees (Australia) Limited | 79,932,576 | 36.99% |
| National Nominees Limited | 33,745,623 | 15.62% |
| Dottie Investments Pty Ltd | 9,166,619 | 4.24% |
| Mutual Trust Pty Ltd | 7,746,054 | 3.58% |
| Howarth PAF Pty Ltd <The Howarth Foundation A/C> | 5,415,675 | 2.51% |
| J P Morgan Nominees Australian Pty Limited | 4,822,719 | 2.23% |
| Equity Plan Services Pty Ltd | 4,582,482 | 2.12% |
| BNP Paribas Nominees Pty Ltd <ACF Clearstream A/C> | 4,014,796 | 1.86% |
| Caroline House Superannuation Fund Pty Ltd | 3,000,000 | 1.39% |
| Timbina Pty Ltd <Timbina Super Fund A/C> | 2,696,297 | 1.25% |
| Ginga Pty Ltd | 2,169,045 | 1.00% |
| P Neustadt Holdings Pty Ltd <Belgove Super Fund A/C> | 2,153,628 | 1.00% |
| Belgove Pty Ltd | 2,053,265 | 0.95% |
| Ginga Pty Ltd <TG Klinger Super Fund A/C> | 2,000,000 | 0.92% |
| Golden Words Pty Ltd | 1,947,082 | 0.90% |
| Mr Nicholas Dermott McDonald | 1,706,000 | 0.79% |
| Mr Gaetano Alfred Gerrard Russo & Ms Deanne Maree Bevan | 1,390,220 | 0.64% |
| REM Medical Pty Ltd <Cocoon Super Fund A/C> | 1,342,801 | 0.62% |
| Howarth PAF Pty Ltd <Howarth Charitable Fund A/C> | 1,315,225 | 0.61% |
| Dinwoodie Investments Pty Ltd | 1,257,004 | 0.58% |